Johnson & Johnson Is Walking Away From a $100 Billion Obesity Market. Could That Actually Make It the Better Long-Term Buy Than Eli Lilly?

Johnson & Johnson is deliberately avoiding the competitive GLP-1 weight-loss drug market, instead focusing on oncology and its medical device business where it has established strengths. This diversified strategy, combined with a lower valuation (P/E of 29x vs. Eli Lilly's 40x+) and higher dividend yield (2.1% vs. 0.6%), may make J&J a more attractive long-term investment despite missing out on the hot obesity drug trend.

07/03/2026, 9:15 PM • The Motley Fool

Here's Why Viking Therapeutics Stock Surged Higher in June

Viking Therapeutics stock rose 19.2% in June driven by optimism over its weight-loss drug pipeline, particularly VK2735, a GLP-1/GIP agonist showing steeper weight loss rates than competitors. The company also initiated a Phase 1 trial for VK3019, a new class of weight-loss drug with a different mechanism. Investors await Phase 3 trial results expected in 2027-2028 and Phase 1 maintenance trial results in Q3 2026.

07/03/2026, 9:25 AM • The Motley Fool

Big Pharma Has a Case of Merger Mania

The pharmaceutical industry is experiencing a record-breaking M&A wave in 2026, driven by looming patent cliffs worth $300 billion in annual revenue, FDA regulatory improvements for rare diseases, and the need to diversify portfolios. Companies are making strategic bolt-on acquisitions of late-stage drug candidates rather than massive mergers. While some firms like Eli Lilly are well-positioned, others like Merck and Pfizer face near-term patent expirations that could impact revenue significantly.

06/30/2026, 12:26 AM • The Motley Fool

Is Septerna a Stock to Sell After an Insider Let Go of 15,000 Shares?

Septerna SVP Daniel D. Long exercised and sold 15,000 shares for ~$533,000 on June 22, 2026, reducing his direct holdings by 13.46%. The analyst suggests this appears to be routine income supplementation rather than a loss of confidence, as Long retains 96,412 shares and 36,000 unexercised options. Septerna, a clinical-stage biotech developing GPCR-targeted therapies, has shown positive phase 1 results for SEP-631 and maintains partnerships with Novo Nordisk.

06/29/2026, 11:05 PM • The Motley Fool

2 Top Growth Stocks to Buy Right Now Without Hesitation

The article recommends MercadoLibre and Eli Lilly as top growth stocks to buy. MercadoLibre dominates e-commerce and fintech across Latin America with a strong logistics network, though it faces competition from Amazon and Temu. Eli Lilly leads the healthcare market with blockbuster GLP-1 drugs (Mounjaro and Zepbound) and is expanding manufacturing capacity and clinical pipelines in oncology and Alzheimer's disease.

06/29/2026, 5:10 AM • The Motley Fool

Opinion: Pfizer Is a Fantastic Dividend Stock for Income Investors to Buy Right Now

Pfizer offers a compelling 6.9% dividend yield, significantly higher than the S&P 500's 1% yield, making it attractive for income investors despite being deeply out of favor on Wall Street. The stock has fallen 60% from its 2021 peak due to disappointing COVID vaccine sales and struggles in drug development, particularly missing out on the lucrative GLP-1 weight-loss drug category. However, the author argues that Pfizer's challenges are typical industry dynamics and the company's strong history suggests it will recover, making it a potential opportunity for long-term investors willing to tolerate near-term uncertainty.

06/27/2026, 3:15 PM • The Motley Fool

Is Eli Lilly Stock an Undervalued Healthcare Stock to Buy?

Eli Lilly stock reached a new all-time high, driven by its blockbuster weight loss treatment. The company holds dominant market share in the weight loss drug category and is being positioned as a clear winner in the GLP-1 drug space, with analysts highlighting its strong performance at industry conferences.

06/26/2026, 8:15 PM • The Motley Fool

Dyne Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

The article compares two clinical-stage biotech companies: Dyne Therapeutics, which targets rare neuromuscular diseases using its FORCE platform, and Viking Therapeutics, which focuses on the larger weight-loss and metabolic disorder market with its VK2735 candidate. Both companies are unprofitable with significant cash burn, but the author recommends Viking due to the substantially larger market opportunity in obesity treatment, despite competitive pressures from industry giants like Eli Lilly and Novo Nordisk.

06/26/2026, 11:05 AM • The Motley Fool

An Analyst Just Declared Eli Lilly the "Clear Winner" of an American Diabetes Association Conference Focused on Weight-Loss Drugs. Novo's Chief Scientist Disagrees. Who's Right?

RBC analyst Trung Huynh declared Eli Lilly the 'clear winner' at the American Diabetes Association conference, citing positive trial data for retatrutide and Foundayo. However, Novo Nordisk's chief science officer Martin Holst Lange argues the competition is far from over, noting that tolerability and effectiveness against comorbidities will play important roles. Eli Lilly reported 56% revenue growth last quarter, while Novo Nordisk experienced negative adjusted sales growth, creating a significant valuation gap between the two companies.

06/25/2026, 11:18 AM • The Motley Fool

Zealthy Expands Insurance Coordination for GLP-1 Weight-Loss Medications

Zealthy announced an expansion of its insurance-coordination program to support eligible patients prescribed GLP-1 weight-loss medications like Wegovy, Zepbound, Ozempic, and Mounjaro. The enhanced program streamlines prior-authorization submissions, insurance verification, and coverage determinations while maintaining that insurance companies retain full authority over approval decisions and patient costs.

06/23/2026, 4:52 PM • GlobeNewswire

Novo Nordisk A/S - share repurchase programme

Novo Nordisk announced progress on its DKK 15 billion share repurchase programme initiated on 6 May 2026. As of 19 June 2026, the company has repurchased 20,959,179 B shares at an average price of DKK 266.09 per share, totaling DKK 5,577,005,168. The company now holds 38,144,480 B shares as treasury shares, representing 0.9% of share capital.

06/22/2026, 8:51 AM • GlobeNewswire

TheDoseReport Announces Which GLP-1 is Best? Semaglutide and Tirzepatide

TheDoseReport.com published a comprehensive comparison of GLP-1 medications, analyzing semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) for weight management. The analysis highlights that tirzepatide demonstrates greater average weight loss (20.2%) compared to semaglutide (13.7%), though both are effective. The article emphasizes the importance of consulting healthcare professionals and considering individual factors including medical history, cost, side effects, and lifestyle support when choosing between these medications.

06/21/2026, 7:33 AM • GlobeNewswire

Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026?

The article compares two emerging biotech stocks: Intellia Therapeutics, which focuses on CRISPR gene-editing technology with promising Phase III trial data but significant losses and clinical risks, and Omeros, which recently achieved FDA approval for Yartemlea and posted its first commercial revenue of $9.89 million. While Intellia offers higher upside potential, Omeros is deemed the safer choice due to its transition to profitability, strong initial sales, and healthier balance sheet, despite trading at a premium valuation.

06/20/2026, 11:02 AM • The Motley Fool

[Latest] Global GLP-1 Receptor Agonist Market Size/Share Worth USD 95.3 Billion by 2035 at a 12.1% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

The global GLP-1 receptor agonist market, valued at USD 28.7 billion in 2025, is projected to grow to USD 95.3 billion by 2035 at a 12.1% CAGR. Growth is driven by rising type 2 diabetes and obesity cases, technological innovations including oral formulations, and expanded insurance coverage. North America leads the market while Asia Pacific shows the highest growth rate.

06/16/2026, 6:30 PM • GlobeNewswire

3 Under-the-Radar Stocks to Buy and Hold for a Decade

The article highlights three biotech companies with strong growth potential over the next decade: Madrigal Pharmaceuticals, which has the first-approved MASH treatment with significant market opportunity; Axsome Therapeutics, which is expanding its depression medicine Auvelity into Alzheimer's disease treatment; and Kailera Therapeutics, a newly public company developing weight-loss medicines in a fast-growing market. All three operate in high-need therapeutic areas with promising pipelines.

06/16/2026, 3:30 AM • The Motley Fool